|
|
|
| |
 |
|
|
|
推薦指數：
|
|
- 內容介紹
|
Local Drug Delivery for Coronary Artery Disease :Established and Emerging Applications
Edited by: Edoardo Camenzind, Ivan De Scheerder
Publisher: Taylor & Francis
ISBN: 1841840459
Pub Date: 10 FEB 2005
Type: Hardback Book
Pioneers in the field, the editors of Local Drug Delivery for Coronary Artery Disease have assembled an excellent team of contributors with extensive experience of threatened vessel closure and restenosis, acute thrombosis, hyperproliferative cellular response, stents and local drug delivery.
Contents:
Part A: General Introduction
1. Introduction 2. Purposes of the Site-specific Therapy: Arterial Wall Passivation 3. Local Drug Delivery: Impact of Pressure, Substance Characteristics and Stenting on Drug Transfer Into the Arterial Wall
Part B: Syllabus of the Platforms for Local Vascular Drug Delivery
4. Catheter-based and Stent-based Treatment for Coronary Artery Disease 5. The ClearWay ^T Microporous Balloon Catheter 6. DISPATCH^T® Coronary Infusion Catheter 7. REMEDY^T PTCA Dilatation Infusion Catheter 8. Infiltrator Angioplasty Balloon Catheter 9. The Infiltrator Local Drug Delivery Catheter 10. The Needle Catheter 11. Stent Mediated Local Drug Delivery
Part C: Inert and Non-eluting Coatings
12. Silicon Carbide-coated Stents 13. Carbostent: A Carbofilm ^T Coated Stent 14. The PC-coated BiodivYsio ^T Stent 15. PTFE Covered Stent
Part D: Drug Eluting Coatings
16. Overview About Drug Delivery Coatings 17. Phosphorylcholine (PC Technology ) Coated Stents as a Drug Delivery Platform 18. Direct Stent Coating: An Alternative for Polymers? 19. Radioactive Stents
Part E: Syllabus of Therapeutic Agents
20. Overview of Potential Interesting Drugs to Inhibit In-stent Restenosis 21. Direct Antithrombins 22. Tissue Factor Inhibitors 23. Nitric Oxide Related Interventions and Restenosis 24. Vitamin E and its Multiple Properties: Anti, Pro, and Non-oxidative Activities 25. Dexamethasone Eluting Stent 26. Anti-inflammatory Approaches to Restenosis 27. The Role of Matrix Metalloproteinases Inhibitors after Arterial Injury 28. Methotrexate: A Potential Interesting Drug for Stent Mediated Local Drug Delivery Anti-inflammatory and Anti-proliferative Characteristics 29. Actin-skeleton Inhibitors: Potential Candidates for Local Drug Delivery in the Prevention of an In-stent Restenosis? 30.Local Delivery of Antisense Oligomers to c-myc for the Prevention of Restenosis
Part F: Pre-clinical Studies
Catheter-based Intravascular Delivery
31. Site Specific Delivery of Cytostatica 32. Catheter-based Delivery of NOS Gene
Stent-based Intravascular Delivery
33. Carbon Coated Stents: Diamond-like Stent Coatings 34. Long-term Biocompatibility Evaluation of Poly-bis-trifluor-ethoxy Phosphazene (PTFEP), a Novel Biodegradable Polymer Stent Coating in a Porcine Coronary Stent Model 35. Biologcompatibility Evaluation of Biological Dissolvable Stent Coatings in a Porcine Coronary Stent Model 36. Glycoprotein GIIb/IIIa Receptor Antagonist-eluting Stents 37. Activated Protein C-eluting Stents 38. Local Methylprednisolone Delivery Using a BiodivYsio Phosphorylcholine Coated Drug Delivery Stents Reduces Inflammation and Neointimal Hyperplasia in a Porcine Coronary Stent Model 39. Methotrexate Loaded SAE-coated Coronary Stents Reduce Neointimal Hyperplasia in a Porcine Coronary Model 40. Rapamycin Eluting Stents 41. Pre-clinical Evaluation of Tacrolimus Coated Coronary Stents 42. Local Delivery of Paclitaxel as a Stent Coating 43. Addition of Cytochalasin D to a Biodegradable Oil Stent Coating Inhibits Intimal Hyperplasia in a Porcine Coronary Model 44. VEGF-eluting Stents 45. An Advanced Antisense for Local and Stent Based Delivery for Prevention of Restenosis 46. Stent-based Gene Delivery
Part G: Clinical Studies
47. Catheter-based Local Heparin Delivery 48. Local Delivery of Low Molecular Weight Heparins 49. Local Delivery of Steroids before Coronary Stent Implantation 50. Clinical Studies with the Carbostent 51. Gold Coated Stents 52. Heparin-coated Stent Trials 53. The Blue Medical 50%TEMPO Coronary Stent: Pre-clinical Study and the First In-man Pilot Trial 54. Dexamethasone: Mode of Action, Pre-clinical and Clinical Studies 55. The First Human Experience with the 17ß-estradiol-eluting Stent System. The EASTER Trial: Estrogen And Stents To Eliminate Restenosis 56. Batimastat: Mode of Action, Precl
|
|
|
其他相關書藉
[ 
[ 